Floatz logo

t3011

Malignant Ascites

West China HospitalPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Malignant Ascites cohort.

Asset / SponsorPhaseRating
Catumaxomab
Neovii Biotech
Phase 2/3BB
5,5'-DINITROSALICIL
Wuhan YZY Biopharma Co., Ltd.
Phase 3BB
Metformin
University of Chicago
Phase 2B
Molgramostim
Second Affiliated Hospital of Soochow University
Phase 1/2CC
Serplulimab
Second Affiliated Hospital of Soochow University
Phase 1/2CC

View all 14 →

Same molecule, other indications

t3011 is also rated in:

melanomaDormant
CCC
Indicative ·
52 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
50 / 100
View asset →
skin carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →